Dr. David Spiegel, Professor of Chemistry and Pharmacology at Yale, is launching a new startup, Kleo Pharmaceuticals, that will harness the body’s own defenses to fight a number of diseases. Kleo relies on Spiegel’s patented immunotherapies—small molecules that can either recruit antibodies to a disease site or mimic the function of antibodies.

“I’ve been working on ways to use small molecules to modulate and manipulate the immune system,” Spiegel says. “Essentially we are redirecting the body’s own immune defenses to go after disease-causing entities, including bacteria, cancer cells, autoimmune disease and virus particles.”